Dr. Farshid Dayyani is a professor of clinical medicine at
the Division of Hematology/Oncology, Medicine School of Medicine, University of
California, Irvine. He is also a board-certified UCI Health medical oncologist
who specializes in the treatment of cancers of the gastrointestinal tract. He
earned his MD at the University of Munich (2002) and completed his PhD in
Immunology at the University of Munich (2002). He completed a residency in
internal medicine at Beth Israel Deaconess Medical Center in Boston, a teaching
hospital of Harvard Medical School. He also completed a fellowship in medical
oncology at the University of Texas MD Anderson Cancer Center in Houston. His
clinical interests include colorectal, stomach, and esophageal cancers, and
anal carcinoma. His goal is to bring leading-edge treatments to patients with
gastrointestinal cancers through innovative clinical trials and translational
research.
Dr. Farshid Dayyani is a professor of clinical medicine at
the Division of Hematology/Oncology, Medicine School of Medicine, University of
California, Irvine. He is also a board-certified UCI Health medical oncologist
who specializes in the treatment of cancers of the gastrointestinal tract. He
earned his MD at the University of Munich (2002) and completed his PhD in
Immunology at the University of Munich (2002). He completed a residency in
internal medicine at Beth Israel Deaconess Medical Center in Boston, a teaching
hospital of Harvard Medical School. He also completed a fellowship in medical
oncology at the University of Texas MD Anderson Cancer Center in Houston. His
clinical interests include colorectal, stomach, and esophageal cancers, and
anal carcinoma. His goal is to bring leading-edge treatments to patients with
gastrointestinal cancers through innovative clinical trials and translational
research.